Ivabradina Tecnigen (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the electrical pathway that initiates each heartbeat. Inhibiting this current slows the spontaneous depolarisation of pacemaker cells, producing a controlled reduction in heart rate without decreasing the strength of cardiac contraction.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s resting heart rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration steps according to current medical guidelines.

Safety data for ivabradine during pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ivabradina Tecnigen. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for heart‑rate reduction in angina and heart failure is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting blood pressure or myocardial contractility, making it useful when beta‑blockers are contraindicated, not tolerated, or insufficient to achieve target heart rates.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in a refrigerator or freezer.

Ivabradina Tecnigen is taken orally as a whole tablet with a glass of water. It may be taken with or without food, but the same conditions should be maintained for each dose. Patients should follow the dosing schedule prescribed by their clinician and not split or crush the tablet.

The most serious adverse events include severe bradycardia that can lead to syncope, new‑onset atrial fibrillation, significant hypotension, and rare cases of liver enzyme elevation. Patients should seek immediate medical attention if they experience fainting, rapid irregular heartbeat, severe dizziness, or signs of liver dysfunction.

Ivabradine is contraindicated in patients with a resting heart rate below 50 bpm, those with sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), severe hepatic impairment, and in individuals taking strong CYP3A4 inhibitors without appropriate monitoring.